PUBLISHER: Persistence Market Research | PRODUCT CODE: 1713186
PUBLISHER: Persistence Market Research | PRODUCT CODE: 1713186
Neurological Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Persistence Market Research has recently released a comprehensive report on the worldwide market for neurological biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global neurological biomarkers market from 2025 to 2032.
Key Insights:
- Neurological Biomarkers Market Size (2025E): USD 9.5 Billion
- Projected Market Value (2032F): USD 19.1 Billion
- Global Market Growth Rate (CAGR 2025 to 2032): 10.4%
Neurological Biomarkers Market - Report Scope:
Neurological biomarkers are vital for the diagnosis, prognosis, and treatment monitoring of various neurological diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injuries. These biomarkers can be found in biological fluids such as blood, cerebrospinal fluid (CSF), and urine, and they help in identifying molecular signatures that reflect the presence of neurological conditions. The neurological biomarkers market caters to diagnostic labs, healthcare providers, research institutions, and pharmaceutical companies, offering a range of biomarker types, including genetic biomarkers, protein biomarkers, and imaging biomarkers. Market growth is driven by increasing prevalence of neurological disorders, advancements in biomarker discovery, and the rising adoption of personalized medicine.
Market Growth Drivers:
The global neurological biomarkers market is propelled by several key factors, including the growing incidence of neurological diseases such as Alzheimer's and Parkinson's disease, which are becoming more prevalent with an aging global population. The increasing demand for non-invasive diagnostic tests and the ability to detect neurological disorders at earlier stages further drive market expansion. Advances in molecular biology, genomics, and proteomics have led to the identification of novel biomarkers that enhance diagnostic accuracy and treatment outcomes. Moreover, the increasing adoption of personalized medicine and the integration of biomarkers in clinical trials to monitor drug efficacy also contribute to the market's growth.
Market Restraints:
Despite promising growth prospects, the neurological biomarkers market faces challenges related to the high costs associated with biomarker development and testing. Regulatory hurdles and the lack of standardization in biomarker testing also pose significant challenges. Additionally, the complex nature of neurological disorders and the difficulty in obtaining accurate biomarker data from patients, particularly in the case of early-stage diseases, further complicate market penetration. The market also faces barriers in terms of reimbursement issues for biomarker-based tests, especially in emerging markets, limiting widespread adoption.
Market Opportunities:
The neurological biomarkers market presents significant growth opportunities driven by advancements in precision medicine, artificial intelligence (AI), and the increasing role of biomarkers in drug development. The application of biomarkers in predicting disease onset, monitoring disease progression, and assessing treatment responses is opening new avenues for market players. Additionally, there is a growing opportunity for the development of non-invasive and cost-effective biomarkers for early diagnosis, which could significantly expand the patient population benefiting from these diagnostic tools. Strategic partnerships, research investments, and the development of more efficient biomarker testing platforms are crucial for capitalizing on emerging opportunities in this dynamic market.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the neurological biomarkers market globally?
- Which types of biomarkers are most commonly used in the diagnosis and monitoring of neurological diseases?
- How are technological advancements reshaping the competitive landscape of the neurological biomarkers market?
- Who are the key players contributing to the neurological biomarkers market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global neurological biomarkers market?
Competitive Intelligence and Business Strategy:
Leading players in the global neurological biomarkers market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to discover novel biomarkers and develop new diagnostic platforms. Collaborations with academic institutions, healthcare providers, and pharmaceutical companies help accelerate biomarker validation and commercialization. Moreover, the development of AI-driven platforms to enhance the precision of biomarker analysis and improve diagnostic workflows is also gaining traction in the market.
Key Companies Profiled:
- Quanterix
- Amoneta Diagnostics
- Bio-Rad Laboratories, Inc
- Eli Lilly and Company
- IXICO plc
- Biognosys
- Revvity
- Beckman Coulter, Inc.
- PreOmics GmbH
- ADx NeuroSciences NV (A Fujirebio Company)
- Fujirebio
- Brainomix
- Merck KGaA
- Bio-Techne
- Assay Genie
- SomaLogic Operating Co., Inc.
- Siemens Healthineers
- Abbott Laboratories
- Roche Diagnostics
- GE HealthCare
- Imaging Endpoints
Market Segmentation:
Neurological Biomarkers Market Research Segmentation: The neurological biomarkers market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various neurological conditions.
By Biomarkers Type
- Proteomic Biomarkers
- Genomic Biomarkers
- Neuroimaging Biomarkers
- Metabolomics Biomarkers
By Sample
- Blood
- Plasma
- Cerebrospinal Fluid
- Others
By Indication
- Alzheimer's disease (AD)
- Multiple sclerosis (MS)
- Parkinson's disease (PD)
- Autism spectrum disorder (ASD)
- Others
By End-user
- Hospital Labs
- Diagnostic Centers
- Academic & Research Institutes
- Biopharma Companies
- Proteomic Laboratory
- Others
By Region
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Neurological Biomarkers Market Snapshot, 2025-2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
- 3.1. Product Adoption Analysis
- 3.2. Regulatory Landscape
- 3.3. Value Chain Analysis
- 3.4. Key Deals and Mergers
- 3.5. PESTLE Analysis
- 3.6. Porter's Five Force Analysis
4. Global Neurological Biomarkers Market Outlook:
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
- 4.3. Global Neurological Biomarkers Market Outlook: Biomarkers
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Biomarker, 2019-2024
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
- 4.3.3.1. Proteomic Biomarkers
- 4.3.3.2. Genomic Biomarkers
- 4.3.3.3. Neuroimaging Biomarkers
- 4.3.3.4. Metabolomics Biomarkers
- 4.3.4. Market Attractiveness Analysis: Biomarkers
- 4.4. Global Neurological Biomarkers Market Outlook: Sample
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, By Sample, 2019-2024
- 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
- 4.4.3.1. Blood
- 4.4.3.2. Plasma
- 4.4.3.3. Cerebrospinal Fluid
- 4.4.3.4. Others
- 4.4.4. Market Attractiveness Analysis: Sample
- 4.5. Global Neurological Biomarkers Market Outlook: Indication
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 4.5.3.1. Alzheimer's Disease (AD)
- 4.5.3.2. Multiple Sclerosis (MS)
- 4.5.3.3. Parkinson's Disease (PD)
- 4.5.3.4. Autism Spectrum Disorder (ASD)
- 4.5.3.5. Others
- 4.5.4. Market Attractiveness Analysis: Indication
- 4.6. Global Neurological Biomarkers Market Outlook: End-user
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2024
- 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 4.6.3.1. Hospital Labs
- 4.6.3.2. Diagnostic Centers
- 4.6.3.3. Academic & Research Institutes
- 4.6.3.4. Biopharma Companies
- 4.6.3.5. Proteomic Laboratory
- 4.6.3.6. Others
- 4.6.4. Market Attractiveness Analysis: End-user
5. Global Neurological Biomarkers Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
- 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia & Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.3.7. Market Attractiveness Analysis: Region
6. North America Neurological Biomarkers Market Outlook:
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Biomarker
- 6.2.3. By Sample
- 6.2.4. By Indication
- 6.2.5. By End-user
- 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
- 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
- 6.4.1. Proteomic Biomarkers
- 6.4.2. Genomic Biomarkers
- 6.4.3. Neuroimaging Biomarkers
- 6.4.4. Metabolomics Biomarkers
- 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
- 6.5.1. Blood
- 6.5.2. Plasma
- 6.5.3. Cerebrospinal Fluid
- 6.5.4. Others
- 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 6.6.1. Alzheimer's Disease (AD)
- 6.6.2. Multiple Sclerosis (MS)
- 6.6.3. Parkinson's Disease (PD)
- 6.6.4. Autism Spectrum Disorder (ASD)
- 6.6.5. Others
- 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 6.7.1. Hospital Labs
- 6.7.2. Diagnostic Centers
- 6.7.3. Academic & Research Institutes
- 6.7.4. Biopharma Companies
- 6.7.5. Proteomic Laboratory
- 6.7.6. Others
- 6.8. Market Attractiveness Analysis
7. Europe Neurological Biomarkers Market Outlook:
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Biomarker
- 7.2.3. By Sample
- 7.2.4. By Indication
- 7.2.5. By End-user
- 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
- 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
- 7.4.1. Proteomic Biomarkers
- 7.4.2. Genomic Biomarkers
- 7.4.3. Neuroimaging Biomarkers
- 7.4.4. Metabolomics Biomarkers
- 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
- 7.5.1. Blood
- 7.5.2. Plasma
- 7.5.3. Cerebrospinal Fluid
- 7.5.4. Others
- 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 7.6.1. Alzheimer's Disease (AD)
- 7.6.2. Multiple Sclerosis (MS)
- 7.6.3. Parkinson's Disease (PD)
- 7.6.4. Autism Spectrum Disorder (ASD)
- 7.6.5. Others
- 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 7.7.1. Hospital Labs
- 7.7.2. Diagnostic Centers
- 7.7.3. Academic & Research Institutes
- 7.7.4. Biopharma Companies
- 7.7.5. Proteomic Laboratory
- 7.7.6. Others
- 7.8. Market Attractiveness Analysis
8. East Asia Neurological Biomarkers Market Outlook:
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Biomarker
- 8.2.3. By Sample
- 8.2.4. By Indication
- 8.2.5. By End-user
- 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
- 8.4.1. Proteomic Biomarkers
- 8.4.2. Genomic Biomarkers
- 8.4.3. Neuroimaging Biomarkers
- 8.4.4. Metabolomics Biomarkers
- 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
- 8.5.1. Blood
- 8.5.2. Plasma
- 8.5.3. Cerebrospinal Fluid
- 8.5.4. Others
- 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 8.6.1. Alzheimer's Disease (AD)
- 8.6.2. Multiple Sclerosis (MS)
- 8.6.3. Parkinson's Disease (PD)
- 8.6.4. Autism Spectrum Disorder (ASD)
- 8.6.5. Others
- 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 8.7.1. Hospital Labs
- 8.7.2. Diagnostic Centers
- 8.7.3. Academic & Research Institutes
- 8.7.4. Biopharma Companies
- 8.7.5. Proteomic Laboratory
- 8.7.6. Others
- 8.8. Market Attractiveness Analysis
9. South Asia & Oceania Neurological Biomarkers Market Outlook:
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Biomarker
- 9.2.3. By Sample
- 9.2.4. By Indication
- 9.2.5. By End-user
- 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
- 9.4.1. Proteomic Biomarkers
- 9.4.2. Genomic Biomarkers
- 9.4.3. Neuroimaging Biomarkers
- 9.4.4. Metabolomics Biomarkers
- 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
- 9.5.1. Blood
- 9.5.2. Plasma
- 9.5.3. Cerebrospinal Fluid
- 9.5.4. Others
- 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 9.6.1. Alzheimer's Disease (AD)
- 9.6.2. Multiple Sclerosis (MS)
- 9.6.3. Parkinson's Disease (PD)
- 9.6.4. Autism Spectrum Disorder (ASD)
- 9.6.5. Others
- 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 9.7.1. Hospital Labs
- 9.7.2. Diagnostic Centers
- 9.7.3. Academic & Research Institutes
- 9.7.4. Biopharma Companies
- 9.7.5. Proteomic Laboratory
- 9.7.6. Others
- 9.8. Market Attractiveness Analysis
10. Latin America Neurological Biomarkers Market Outlook:
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Biomarker
- 10.2.3. By Sample
- 10.2.4. By Indication
- 10.2.5. By End-user
- 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
- 10.4.1. Proteomic Biomarkers
- 10.4.2. Genomic Biomarkers
- 10.4.3. Neuroimaging Biomarkers
- 10.4.4. Metabolomics Biomarkers
- 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
- 10.5.1. Blood
- 10.5.2. Plasma
- 10.5.3. Cerebrospinal Fluid
- 10.5.4. Others
- 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 10.6.1. Alzheimer's Disease (AD)
- 10.6.2. Multiple Sclerosis (MS)
- 10.6.3. Parkinson's Disease (PD)
- 10.6.4. Autism Spectrum Disorder (ASD)
- 10.6.5. Others
- 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 10.7.1. Hospital Labs
- 10.7.2. Diagnostic Centers
- 10.7.3. Academic & Research Institutes
- 10.7.4. Biopharma Companies
- 10.7.5. Proteomic Laboratory
- 10.7.6. Others
- 10.8. Market Attractiveness Analysis
11. Middle East & Africa Neurological Biomarkers Market Outlook:
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Biomarker
- 11.2.3. By Sample
- 11.2.4. By Indication
- 11.2.5. By End-user
- 11.3. Current Market Size (US$ Bn) and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
- 11.4.1. Proteomic Biomarkers
- 11.4.2. Genomic Biomarkers
- 11.4.3. Neuroimaging Biomarkers
- 11.4.4. Metabolomics Biomarkers
- 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
- 11.5.1. Blood
- 11.5.2. Plasma
- 11.5.3. Cerebrospinal Fluid
- 11.5.4. Others
- 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
- 11.6.1. Alzheimer's Disease (AD)
- 11.6.2. Multiple Sclerosis (MS)
- 11.6.3. Parkinson's Disease (PD)
- 11.6.4. Autism Spectrum Disorder (ASD)
- 11.6.5. Others
- 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
- 11.7.1. Hospital Labs
- 11.7.2. Diagnostic Centers
- 11.7.3. Academic & Research Institutes
- 11.7.4. Biopharma Companies
- 11.7.5. Proteomic Laboratory
- 11.7.6. Others
- 11.8. Market Attractiveness Analysis
12. Competition Landscape
- 12.1. Market Share Analysis, 2025
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Quanterix
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Products
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Amoneta Diagnostics
- 12.3.3. Bio-Rad Laboratories, Inc
- 12.3.4. Eli Lilly and Company
- 12.3.5. IXICO plc
- 12.3.6. Biognosys
- 12.3.7. Revvity
- 12.3.8. Beckman Coulter, Inc.
- 12.3.9. PreOmics GmbH
- 12.3.10. ADx NeuroSciences NV (A Fujirebio Company)
- 12.3.11. Fujirebio
- 12.3.12. Brainomix
- 12.3.13. Merck KGaA
- 12.3.14. Bio-Techne
- 12.3.15. Assay Genie
- 12.3.16. SomaLogic Operating Co., Inc.
- 12.3.17. Siemens Healthineers
- 12.3.18. Abbott Laboratories
- 12.3.19. Roche Diagnostics
- 12.3.20. GE HealthCare
- 12.3.21. Imaging Endpoints
- 12.3.1. Quanterix
13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
